This is consistent with published findings on hepatocellular carcinoma that indicates poor clinical outcomes in patients with high levels of serum acute phase proteins including CRP who are treated with PD-1 inhibitors (11). The gene discussed is CRP; the disease is hepatocellular carcinoma.